Hero

News & Events

Mestag in the News
BioCentury Article: Mestag: Attacking Tumors from Within

BiotechTV Video: Interview with CEO Dr. Susan Hill

Mestag Therapeutics Announces Licensing of a Novel Inflammatory Disease Target from its RAFT Platform

December 9, 2024

Mestag Therapeutics Expands Leadership Team and Appoints Head of Development and General Counsel

November 13, 2024

Mestag Therapeutics Announces License and Research Collaboration with MSD to Identify Novel Targets for Inflammatory Diseases

October 8, 2024

Mestag Therapeutics Awarded Significant Grant from Innovate UK’s Prestigious Cancer Therapeutics Program to Accelerate the Path to the Clinic for MST-0300

August 28, 2024

Mestag Presents Preclinical Data at AACR on its M300 Program, a Conditionally Active LTBR Agonist Designed to Induce Tertiary Lymphoid Structures in Tumors

View All Press Releases

Women in Biotech – London

December 5, 2024

Conference Website

Longwood Healthcare Leaders – San Francisco, CA

M&A and Deal-Making Landscape

January 11, 2025 | 2:30 pm PT

Conference Website